Literature DB >> 21358674

Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway.

A E Thurber1, G Douglas, E C Sturm, S E Zabierowski, D J Smit, S N Ramakrishnan, E Hacker, J H Leonard, M Herlyn, R A Sturm.   

Abstract

The use of adherent monolayer cultures have produced many insights into melanoma cell growth and differentiation, but often novel therapeutics demonstrated to act on these cells are not active in vivo. It is imperative that new methods of growing melanoma cells that reflect growth in vivo are investigated. To this end, a range of human melanoma cell lines passaged as adherent cultures or induced to form melanoma spheres (melanospheres) in stem cell media have been studied to compare cellular characteristics and protein expression. Melanoma spheres and tumours grown from cell lines as mouse xenografts had increased heterogeneity when compared with adherent cells and 3D-spheroids in agar (aggregates). Furthermore, cells within the melanoma spheres and mouse xenografts each displayed a high level of reciprocal BRN2 or MITF expression, which matched more closely the pattern seen in human melanoma tumours in situ, rather than the propensity for co-expression of these important melanocytic transcription factors seen in adherent cells and 3D-spheroids. Notably, when the levels of the BRN2 and MITF proteins were each independently repressed using siRNA treatment of adherent melanoma cells, members of the NOTCH pathway responded by decreasing or increasing expression, respectively. This links BRN2 as an activator, and conversely, MITF as a repressor of the NOTCH pathway in melanoma cells. Loss of the BRN2-MITF axis in antisense-ablated cell lines decreased the melanoma sphere-forming capability, cell adhesion during 3D-spheroid formation and invasion through a collagen matrix. Combined, this evidence suggests that the melanoma sphere-culture system induces subpopulations of cells that may more accurately portray the in vivo disease, than the growth as adherent melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21358674      PMCID: PMC3591523          DOI: 10.1038/onc.2011.33

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  35 in total

Review 1.  The many faces of Notch signaling in skin-derived cells.

Authors:  Chelsea C Pinnix; Meenhard Herlyn
Journal:  Pigment Cell Res       Date:  2007-12

2.  A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.

Authors:  Soledad R Alonso; Lorraine Tracey; Pablo Ortiz; Beatriz Pérez-Gómez; José Palacios; Marina Pollán; Juan Linares; Salvio Serrano; Ana I Sáez-Castillo; Lydia Sánchez; Raquel Pajares; Abel Sánchez-Aguilera; Maria J Artiga; Miguel A Piris; José L Rodríguez-Peralto
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

Review 3.  Reprogramming metastatic tumour cells with embryonic microenvironments.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Richard E B Seftor; Jennifer Kasemeier-Kulesa; Paul M Kulesa; Lynne-Marie Postovit
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

4.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

5.  Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype.

Authors:  Darren J Smit; Brooke B Gardiner; Richard A Sturm
Journal:  Int J Cancer       Date:  2007-12-15       Impact factor: 7.396

6.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

7.  Post-transcriptional regulation of melanin biosynthetic enzymes by cAMP and resveratrol in human melanocytes.

Authors:  Richard A Newton; Anthony L Cook; Donald W Roberts; J Helen Leonard; Richard A Sturm
Journal:  J Invest Dermatol       Date:  2007-04-26       Impact factor: 8.551

8.  Confirmation of a BRAF mutation-associated gene expression signature in melanoma.

Authors:  Peter Johansson; Sandra Pavey; Nicholas Hayward
Journal:  Pigment Cell Res       Date:  2007-06

Review 9.  Immunohistochemical characteristics of melanoma.

Authors:  Steven J Ohsie; G Peter Sarantopoulos; Alistair J Cochran; Scott W Binder
Journal:  J Cutan Pathol       Date:  2008-05       Impact factor: 1.587

10.  In vivo switching of human melanoma cells between proliferative and invasive states.

Authors:  Keith S Hoek; Ossia M Eichhoff; Natalie C Schlegel; Udo Döbbeling; Nikita Kobert; Leo Schaerer; Silvio Hemmi; Reinhard Dummer
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

View more
  39 in total

1.  Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.

Authors:  G Denecker; N Vandamme; O Akay; D Koludrovic; J Taminau; K Lemeire; A Gheldof; B De Craene; M Van Gele; L Brochez; G M Udupi; M Rafferty; B Balint; W M Gallagher; G Ghanem; D Huylebroeck; J Haigh; J van den Oord; L Larue; I Davidson; J-C Marine; G Berx
Journal:  Cell Death Differ       Date:  2014-04-25       Impact factor: 15.828

Review 2.  Pro-survival role of MITF in melanoma.

Authors:  Mariusz L Hartman; Malgorzata Czyz
Journal:  J Invest Dermatol       Date:  2014-08-21       Impact factor: 8.551

Review 3.  Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.

Authors:  Ross L Pearlman; Mary Katherine Montes de Oca; Harish Chandra Pal; Farrukh Afaq
Journal:  Cancer Lett       Date:  2017-01-25       Impact factor: 8.679

4.  Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation.

Authors:  Irina Berlin; Laurence Denat; Anne-Lise Steunou; Isabel Puig; Delphine Champeval; Sophie Colombo; Karen Roberts; Elise Bonvin; Yveline Bourgeois; Irwin Davidson; Véronique Delmas; Laurence Nieto; Colin R Goding; Lionel Larue
Journal:  Mol Cell Biol       Date:  2012-01-30       Impact factor: 4.272

5.  Phenotypic diversity of patient-derived melanoma populations in stem cell medium.

Authors:  Malgorzata Sztiller-Sikorska; Mariusz L Hartman; Beata Talar; Justyna Jakubowska; Izabela Zalesna; Malgorzata Czyz
Journal:  Lab Invest       Date:  2015-04-13       Impact factor: 5.662

Review 6.  Culturing Uveal Melanoma Cells.

Authors:  Martina Angi; Mieke Versluis; Helen Kalirai
Journal:  Ocul Oncol Pathol       Date:  2015-04-09

7.  Single-cell gene expression signatures reveal melanoma cell heterogeneity.

Authors:  M Ennen; C Keime; D Kobi; G Mengus; D Lipsker; C Thibault-Carpentier; I Davidson
Journal:  Oncogene       Date:  2014-08-18       Impact factor: 9.867

8.  Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients.

Authors:  Richard A Sturm; Carly Fox; Phil McClenahan; Kasturee Jagirdar; Maider Ibarrola-Villava; Parastoo Banan; Nicola C Abbott; Gloria Ribas; Brian Gabrielli; David L Duffy; H Peter Soyer
Journal:  J Invest Dermatol       Date:  2013-06-17       Impact factor: 8.551

9.  A phosphatidylinositol 3-kinase-Pax3 axis regulates Brn-2 expression in melanoma.

Authors:  Elise Bonvin; Paola Falletta; Heather Shaw; Veronique Delmas; Colin R Goding
Journal:  Mol Cell Biol       Date:  2012-09-17       Impact factor: 4.272

Review 10.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.